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Abstract : An 82-year-old woman had been taking alendronate for 5 years and 5 
months, which had been prescribed for osteoporosis at a local clinic.  Severe left 
thigh pain began without any trauma.  X-ray, computed tomography and magnetic 
resonance imaging findings showed atypical femoral fracture（AFF）.  Treatment 
with teriparatide and weight-bearing therapy was selected.  Bone union was 
achieved without surgery.  Teriparatide has been reported to promote AFF healing.  
At four years and 9 months from the beginning of treatment, our patient has no 
left femoral pain and no impairment to activities of daily living.  Careful follow-up 
will be necessary as long-term outcomes of conservative AFF treatment have not 
been reported to date.
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Introduction
　We report the case of a patient who sustained an atypical femoral fracture （AFF） during 
alendronate therapy for osteoporosis.  Bone union was achieved with concurrent teriparatide 
administration and weight-bearing therapy.
Case report
　We treated an 82-year-old woman whose chief complaint was left femoral pain.  She had no 
recent history of trauma, but she had previously been diagnosed with osteoporosis and had been 
taking 35 mg of alendronate once weekly for 5 years and 5 months.  On developing idiopathic 
left femoral pain, she was treated with non-steroidal anti-inflammatory drugs by a local physician. 
However, her symptoms were not alleviated.  Therefore, she was referred to our hospital 
3 months after she first experienced the pain.  On initial examination, the patient had gait 
disturbance and experienced pain while turning over in bed.  X-ray images showed a transverse 
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fracture in the left femoral shaft that extended to about half the bone diameter （Fig. 1）. 
Computed tomography confirmed cortical bone thickening and the fracture line.  Fat-suppressed 
magnetic resonance imaging （MRI） showed high signal intensity （Fig. 2）.  No malignant 
lesions were observed.  A plain radiograph of the right femur showed cortical thickness but no 
radiolucent line.
　The patient’s blood bone biochemistry showed that she had abnormally low levels of 
metabolic markers for bone turnover, including P1NP （15.4 µg / l, range, 16.4-98.2 µg / l）.  Her 
Fig. 1.  Plain radiograph showing cortical thickness with radiolucent 
line （white arrow）  
a：Anterior–posterior view, b：Lateral view. 
Fig. 2.   Computed tomography and magnetic 
resonance imaging scans showing a left 
femur fracture
a： Computed tomography scan showing cortical 
thickness with radiolucent line （white arrow）.
b： Magnetic resonance imaging scan showing 
signal intensity change （white arrow）.
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bone mineral density relative to the young adult mean was 58％ for the distal one-third of 
the radius, 78％ for the femoral neck, and 82％ for the anterior–posterior density of the L2–
L4 vertebrae.  Based on clinical and imaging findings, we diagnosed bisphosphonate-induced 
atypical fracture.  The patient was hospitalized for treatment because she lived alone and had 
difficulty with activities of daily living.  Subsequently, teriparatide therapy （56.5 µg teriparatide 
acetate per week）was initiated and we established an exercise program of walking with partial 
（half）weight-bearing using double crutches.  The patient was discharged 3 weeks after her 
gait stabilized.  After 4 weeks of teriparatide therapy, the pain had been alleviated.  An MRI 
scan showed a decrease in the luminosity change, standard x-ray images showed an increase 
in callus formation, and the patient could walk with full weight-bearing using crutches.  Three 
months after treatment initiation, she could walk unassisted.  At 4 months, her condition had 
further improved.  In addition, the signal intensity changes that were previously evident on MRI 
scanning had mostly disappeared （Fig. 3）.  Four years and 9 months since her treatment began, 
she has no left femoral pain and no impairment to activities of daily living.
Discussion
　During treatment of osteoporosis with bisphosphonate, bone metabolism is excessively 
suppressed, which can cause AFF.  The incidence of AFF increases with the use of 
bisphosphonate for more than 5 years1）, although a shorter duration of therapy may also lead 
to AFF2, 3）.  Interestingly, a diagnostic criteria task force of the American Society for Bone 
and Mineral Research has reported the involvement of femoral curvature 4–7）.  Thus, the exact 
pathological process is unclear, and the treatment strategy for AFF is controversial.  Also, cases 
of delayed union in patients treated with bisphosphonates have been reported 8–10）.  However, by 
treating our patient with teriparatide, we achieved bone union much sooner than described in 
Fig. 3.  Magnetic resonance imaging scans showing change in signal intensity 
a：2 months after initial treatment.
b：3 months after initial treatment.
c：4 months after initial treatment.
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other reported cases of healed fractures10, 11）.  In reports of conservative treatment, surgery was 
required more often for subtrochanteric fractures than for diaphyseal（shaft）fractures12）.  The 
present patient sustained a femoral shaft fracture, which we were able to treat conservatively. 
A case of subtrochanteric AFF in which bone union was achieved following intramedullary 
nail fixation and administration of teriparatide therapy has also been reported9）.  However, we 
were able to achieve bone union before complete bone fracture occurred.  In cases of complete 
fracture, further treatment would be needed to prevent the onset of displacement.  Generally, 
conservative treatment is only an option for cases of incomplete fracture13）, but AFF rarely 
heals spontaneously and most patients require surgery14, 15）.  Specifically, teriparatide appears to 
promote AFF healing16）, so weight-bearing gait rehabilitation during teriparatide treatment 17, 18） 
might be a good conservative treatment option for some patients.  We believe that teriparatide 
therapy enhanced the bone union in our patient.  We also believe that teriparatide treatment is 
likely to result in acceptable long-term outcomes, given the medium-term clinical success achieved 
with our patient.
Conclusion
　We report our experience of treating a patient who developed an atypical fracture after 5 
years and 5 months of alendronate therapy.  The bone fracture site healed following teriparatide 
therapy.  We conclude that conservative treatment might be a good treatment option in such 
cases.
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